Halo CSTDs are designed to protect health care professionals from exposure to hazardous drugs that can have serious health effects, including cancers.
The US Food and Drug Administration (FDA) has approved the Halo Closed System Transfer Device (CSTD) of the first product of the emerging medical device firm, Corvida Medical. Thousands of health care workers are exposed to hazardous drugs every year. This exposure can lead to serious health effects, including cancers, infertility, genetic mutations, and other health issues.
The company officials explain that CSTDs are designed to protect health care professionals and patients from exposure to these drugs by mechanically prohibiting the transfer of environmental contaminants into the system and the escape of drug or vapor concentrations outside the system.
Halo provides health care professionals with an air-tight and leak-proof closed system that is easy to use, with fewer pieces and fewer steps. It features a simple design that enhances comfort, while ensuring compatibility with existing work procedures.
“We are focused on developing and introducing products designed to meet critical unmet needs, and have worked closely with thought leaders throughout our product development efforts. The feedback on Halo has been phenomena. Health care professionals appreciate Halo’s simplicity and we look forward to introducing it to the market,” commented Kent Smith, President and CEO of Corvida Medical.
The Halo will be commercially available in late 2015.
Advertisement